🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Czechia
Clinical trial register · Czechia

Studies with a Czech investigative site

Every study on the ClinicalTrials.gov registry that lists a site in Czechia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1510 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:45 UTC
1510
Studies in scope
all four open statuses
786
Recruiting now
open to new participants
301
Lead sponsors
across recruiting studies
Top sites
Prague 1080 Brno 606 Olomouc 325 Hradec Králové 320 Ostrava 279
Narrow the register
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals70 Charles University, Czech Republic54 AstraZeneca50 Eli Lilly and Company48 Merck Sharp & Dohme LLC46
Site location
Prague1080 Brno606 Olomouc325 Hradec Králové320 Ostrava279
All 211 locations
Target enrolment
to

Trials in this register

1510 of 1510 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Czechia
Start
Recruiting
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
NCT05337631HNSCC, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer
University Hospital Freiburg
Observational
1,500
Brno
2021-06-01
Active, closed
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
NCT04810078Clear Cell Renal Cell Carcinoma
DrugsNivolumab and rHuPH20·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
681
Brno, Hradec Králové, Olomouc, Ostrava, Prague, Praha 8 Liben
2021-05-21
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Brno, Ostrava
2021-05-15
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
DrugsTalazoparib·Enzalutamide
Pfizer
Phase 3
599
Olomouc, Ostrava - Poruba, Prague, Praha 8- Liben
2021-05-12
Recruiting
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 3
815
Prague
2021-05-12
Active, closed
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Diffuse Large B-cell Lymphoma
DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone
Incyte Corporation
Phase 3
899
Brno, Hradec Králové, Olomouc, Ostrava, Prague
2021-05-11
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
DrugAlectinib
Hoffmann-La Roche
Observational
800
Brno, Olomouc, Praha 4 - Krc
2021-05-10
By invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)
DrugAficamten
Cytokinetics
Phase 2/3
900
Prague
2021-05-06
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab
Hoffmann-La Roche
Phase 3
1,188
Brno, Hradec Králové, Nový Jičín, Olomouc, Prague, Praha 4 - Krc
2021-05-04
Active, closed
Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
NCT04818502Mitral Valve Regurgitation
Abbott Medical Devices
Observational
200
Olomouc, Prague, Třinec
2021-05-04
Active, closed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344Muscle-invasive Bladder Cancer
DrugAtezolizumab
Hoffmann-La Roche
Phase 3
761
Olomouc, Prague, Praha 4 - Krc
2021-05-03
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
NCT04752774Spasticity
DrugsDysport·Corabotase
Ipsen
Phase 1/2
240
Hradec Králové, Jihlava, Ostrava, Pardubice, Prague
2021-04-29
Active, closed
A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
NCT04825743ST-elevation Myocardial Infarction (STEMI)
CeleCor Therapeutics
Phase 3
2,463
Brno
2021-04-24
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
808
Brno, Hradec Králové, Olomouc, Prague
2021-04-21
Active, closed
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma
DrugsTafasitamab·Lenalidomide·Rituximab
Incyte Corporation
Phase 3
654
Brno, Hradec Králové, Ostrava, Prague
2021-04-15
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda
Merck Sharp & Dohme LLC
Phase 3
1,854
Brno, Nový Jičín, Ostrava, Olomouc, Prague
2021-04-14
Active, closed
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
DrugsIxekizumab·Adalimumab
Eli Lilly and Company
Phase 3
101
Prague, Olomouc
2021-04-13
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Hradec Králové, Olomouc
2021-04-09
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib
Loxo Oncology, Inc.
Phase 3
500
Hradec Králové, Brno
2021-04-08
Active, closed
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
NCT04816604Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 2
74
Prague
2021-04-05
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Brno, Hradec Králové
2021-04-05
Recruiting
COVID-19 Vaccines Safety Tracking (CoVaST)
NCT04834869Adverse Reaction to Vaccine, COVID19 Vaccine
DrugsComirnaty·Efluelda (TIV-HD) and Spikevax
Masaryk University
Observational
30,000
Brno
2021-04-01
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
DrugSemaglutide
Novo Nordisk A/S
Phase 3
1,205
Liberec, Pilsen, Prague
2021-04-01
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
DrugFluzoparib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Nový Jičín, Prague
2021-03-18
Recruiting
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
NCT04715646Epilepsy
DrugBrivaracetam
UCB Biopharma SRL
Phase 3
70
Prague
2021-03-11
Active, closed
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389Myelofibrosis
DrugsSelinexor·Ruxolitinib
Karyopharm Therapeutics Inc
Phase 3
353
Prague, Hradec Králové, Olomouc
2021-03-11
Active, closed
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine
Loxo Oncology, Inc.
Phase 3
238
Brno, Hradec Králové, Prague
2021-03-09
Recruiting
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
NCT04766866Preeclampsia, Intrauterine Growth Restriction, Maternal Hypertension, Neonatal Outcome
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Not applicable
9,132
Prague
2021-03-02
Recruiting
Factors Affecting the Quality of Life After Ischemic Stroke in Young Adults
NCT04839887Ischemic Stroke
Elena Gurkova
Observational
520
Olomouc
2021-03-01
Active, closed
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
313
Prague
2021-02-25
Active, closed
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04586231Carcinoma, Renal Cell
DrugsBelzutifan·Cabozantinib·Lenvatinib
Merck Sharp & Dohme LLC
Phase 3
747
Brno, Prague, České Budějovice, Hradec Králové
2021-02-25
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Nový Hradec Králové, Ostrava, Prague
2021-02-23
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
DrugsAdagrasib·Taxotere·Docetaxel
Mirati Therapeutics Inc.
Phase 3
453
Hořovice, Olomouc, Prague, Praha 8 - Liben
2021-02-23
Active, closed
Predictive Markers of the Course of Covid-19 Based on Biomarker Serum Amyloid A (SAA) and Genetic Markers
NCT07120269COVID-19
Thomayer University Hospital
Not applicable
500
Prague
2021-02-10
Recruiting
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04901936Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
DrugPegcetacoplan
Apellis Pharmaceuticals, Inc.
Phase 2
12
Prague
2021-02-04
Active, closed
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
NCT04755283Atrial Fibrillation (AF), Stroke
DrugsAbelacimab·Rivaroxaban
Anthos Therapeutics, Inc.
Phase 2
1,287
Brandýs nad Labem, Poděbrady, Příbram, Slaný, Mariánské Lázně, Trutnov, Liberec, Česká Lípa
2021-02-02
Recruiting
SCAD : a Registry of Spontaneous Coronary Artery Dissection
NCT06601270Spontaneous Coronary Artery Dissection
European Society of Cardiology
Observational
1,500
Pardubice, Prague
2021-01-30
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Palbociclib
AstraZeneca
Phase 3
1,370
Hořovice, Hradec Králové, Nový Jičín, Prague
2021-01-28
Recruiting
Prehabilitation in Gynaecological Cancer Patients
NCT04789694Ovarian Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Endometrial Cancer
Charles University, Czech Republic
Phase 3
64
Prague
2021-01-25
Active, closed
Comparison of the Accuracy of US, MRI and PET/CT in the Assessment of LNs in Cervical Cancer.
NCT05573451Lymph Node Metastasis, Cervical Cancer
General University Hospital, Prague
Observational
91
Prague
2021-01-20
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
250
Brno, Prague
2021-01-20
Active, closed
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
NCT04657991Melanoma
DrugsBinimetinib·Encorafenib·Keytruda·Pembrolizumab
Pfizer
Phase 3
257
Olomouc, Ostrava-Poruba, Praha 8-Liben
2021-01-15
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
DrugsKeytruda·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
990
Brno, Prague, Olomouc
2021-01-10
Active, closed
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
DrugPembrolizumab
BioNTech SE
Phase 2/3
358
Olomouc, Prague 8 - Liben
2021-01-07
Active, closed
Transorbital Ultrasound and Other Markers for Prognosis Prediction After Cardiac Arrest
NCT04838418Cardiac Arrest
University Hospital Pilsen
Observational
80
Pilsen
2021-01-04
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Ostrava, Brno-Zidonice, Prague, Brno, Hradec Králové, Uherské Hradiště
2020-12-22
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
DrugsEncorafenib·5-FU·Leucovorin·Cetuximab
Pfizer
Phase 3
841
Brno, Hradec Králové, Prague, Olomouc
2020-12-21
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Docetaxel
Daiichi Sankyo
Phase 3
605
Prague
2020-12-21
Active, closed
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
NCT04641442NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
DrugMAS825
Novartis Pharmaceuticals
Phase 2
17
Prague
2020-12-18
Active, closed
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Biosciences
Phase 3
182
Hradec Králové
2020-12-16
Active, closed
Triac Trial II in MCT8 Deficiency Patients
NCT02396459Allan-Herndon-Dudley Syndrome
Rare Thyroid Therapeutics International AB
Phase 2
22
Prague
2020-12-07
Active, closed
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin
Janssen Research & Development, LLC
Phase 3
518
Opava, Plzen-Bory, Prague
2020-12-07
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Brno, Prague
2020-12-04
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Hořovice, Olomouc, Ostrava, Prague, Praha 8 - Liben
2020-12-02
Active, closed
Switch of AndroidAPS to Commercially Available AID Systems
NCT06709729Diabetes Mellitus, Type 1
Charles University, Czech Republic
Not applicable
41
Prague
2020-12-01
Active, closed
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax
Genmab
Phase 1/2
194
Prague, Hradec Králové, Ostrava, Brno, Olomouc
2020-11-25
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
DrugsSaruparib·Camizestrant·Datopotamab Deruxtecan·Trastuzumab deruxtecan
AstraZeneca
Phase 1/2
702
Brno, Prague
2020-11-12
Active, closed
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059Prostatic Neoplasms
DrugsLhrha·Apalutamide
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Pilsen, Prague
2020-11-12
Active, closed
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
NCT04597125Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer
Phase 4
654
Liberec, Prague, Brno, Chomutov
2020-11-09
Active, closed
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
NCT04512235AL Amyloidosis
DrugsAnselamimab·Cyclophosphamide, bortezomib, and dexamethasone (CyBorD)
Alexion Pharmaceuticals, Inc.
Phase 3
281
Ostrava Poruba, Prague
2020-11-03
Active, closed
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
DrugsR-Ice·Rituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab
Genmab
Phase 1/2
543
Hradec Králové, Ostrava - Poruba, Prague
2020-11-03
Recruiting
OSA as a Remote Ischemic Preconditioning in Vascular Surgery
NCT04630535Obstructive Sleep Apnea, Vascular Aneurysm, Ischemia Reperfusion Injury
St. Anne's University Hospital Brno, Czech Republic
Observational
100
Brno
2020-11-01
Active, closed
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
NCT04598893Diabetes Mellitus, Type 1
DrugTeplizumab
Provention Bio, a Sanofi Company
Observational
188
Prague
2020-10-26
By invitation
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
NCT04574076Haemophilia A
DrugTuroctocog alfa pegol
Novo Nordisk A/S
Observational
60
Brno, Hradec Králové
2020-10-23
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
DrugDarolutamide
Bayer
Phase 3
402
Jablonec nad Nisou, Prague, Brno
2020-10-20
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma
DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate
Exelixis
Phase 3
575
Prague, Brno, Olomouc
2020-10-19
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone
Acerta Pharma BV
Phase 3
611
Brno, Hradec Králové, Ostrava - Poruba, Pilsen, Prague
2020-10-08
By invitation
The Medical Management in Patients Exposed to Weapons of Mass Destruction
NCT05026645Chemical Injury, Chemicals; Intoxication, Acute Respiratory Distress Syndrome, Distress Respiratory Syndrome
St. Justine's Hospital
Observational
1,000
Prague
2020-10-01
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone
GlaxoSmithKline
Phase 3
302
Brno, Hradec Králové, Prague
2020-10-01
Active, closed
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611Crohn's Disease (CD)
DrugsSkyrizi·Risankizumab·Ustekinumab
AbbVie
Phase 3
527
Prague, České Budějovice, Hradec Králové, Pardubice
2020-09-30
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584Paroxysmal Nocturnal Hemoglobinuria
DrugsCrovalimab·Eculizumab
Hoffmann-La Roche
Phase 3
190
Prague
2020-09-30
Active, closed
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
NCT04483739Multiple Myeloma
European Myeloma Network B.V.
Phase 3
302
Brno, Nový Hradec Králové, Ostrava, Prague
2020-09-25
Active, closed
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
DrugsPF-07220060·Midazolam
Pfizer
Phase 2
362
Prague
2020-09-23
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
DrugsAbiraterone acetate·Prednisone
Janssen Research & Development, LLC
Phase 3
696
Brno, Hradec Králové, Liberec, Olomouc, Prague
2020-09-23
Active, closed
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
DrugEfgartigimod PH20
argenx
Phase 2
229
Hradec Králové
2020-09-18
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907Rhabdomyosarcoma
DrugsActinomycin-D·Dactinomycin·Ifosfamide·Vinorelbine
University of Birmingham
Phase 1/2
1,672
Brno
2020-09-17
Active, closed
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
DrugsLoncastuximab Tesirine·Rituximab·Oxaliplatin·Gemcitabine
ADC Therapeutics S.A.
Phase 3
440
Ostrava, Prague
2020-09-16
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
DrugsVenclexta·Azacitidine·Venetoclax
AbbVie
Phase 3
531
Brno, Hradec Králové, Ostrava, Pilsen, Prague
2020-09-10
Recruiting
Gait Recovery in Patients After Acute Ischemic Stroke
NCT04824482Ischemic Stroke
University Hospital Olomouc
Not applicable
120
Olomouc
2020-09-01
Recruiting
Immune Homeostasis in Sepsis and Septic Shock
NCT04448951Sepsis, Immunologic Paralysis, Immunologic Suppression, Immune Deficiency
Charles University, Czech Republic
Observational
200
Pilsen
2020-09-01
Active, closed
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04468984Myelofibrosis (MF)
DrugsNavitoclax·Ruxolitinib
AbbVie
Phase 3
330
Brno, Prague
2020-08-31
Active, closed
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma
DrugsOregovomab·Paraplatin·Taxol·Paclitaxel
CanariaBio Inc.
Phase 3
615
Hradec Králové, Prague
2020-08-25
Active, closed
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
NCT04504825AL Amyloidosis
DrugsAnselamimab·Cyclophosphamide, bortezomib, and dexamethasone (CyBorD)
Alexion Pharmaceuticals, Inc.
Phase 3
125
Ostrava - Poruba, Prague
2020-08-25
Active, closed
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283Diffuse Large B-cell Lymphoma
DrugsBrentuximab Vedotin·Lenalidomide·Rituximab
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
239
Hradec Králové
2020-08-20
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
NCT04419649Myelodysplastic Syndromes, Cytopenia
DrugElritercept
Takeda
Phase 2
160
Brno, Prague
2020-08-19
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Brno, Hradec Králové, Olomouc, Prague
2020-08-18
Recruiting
Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.
NCT04180397Fluid Overload
DrugFurosemide
Morten H. Bestle
Phase 4
1,000
Ostrava, Pilsen, Prague
2020-08-17
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963Ovarian Cancer, Breast Cancer
DrugOlaparib
AstraZeneca
Phase 3
185
Brno, Olomouc, Ostrava Poruba, Prague
2020-08-04
Active, closed
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
NCT04509700B-Cell Malignancies
DrugsItacitinib·Parsaclisib·Ibrutinib·Ruxolitinib
Incyte Corporation
Phase 2
112
Hradec Králové, Prague
2020-08-03
Active, closed
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358Cholestasis
GlaxoSmithKline
Phase 3
242
Pilsen, Prague
2020-07-14
Active, closed
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
DrugsCapivasertib·Abiraterone acetate
AstraZeneca
Phase 3
1,012
Brno, Hořovice, Hradec Králové, Prague
2020-07-13
Active, closed
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Muscular Dystrophy, Duchenne
DrugEteplirsen
Sarepta Therapeutics, Inc.
Phase 3
160
Brno, Prague
2020-07-13
Recruiting
Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
NCT05982119Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth
Centre Hospitalier Universitaire de Liege
Not applicable
300
Prague
2020-07-10
Active, closed
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
NCT04158934Hemophilia A
Baxalta now part of Shire
Observational
207
Prague, Ústí nad Labem
2020-07-09
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Prague
2020-07-07
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsParaplatin·Taxol·Olaparib·Etoposide
Merck Sharp & Dohme LLC
Phase 3
870
Brno, Ostrava, Prague, Nová Ves pod Pleší, Liberec
2020-07-06
Active, closed
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
NCT04314531Active Psoriatic Arthritis
Sun Pharmaceutical Industries Limited
Phase 3
296
Brno, Prague, Zlín
2020-07-01
Active, closed
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945Pulmonary Arterial Hypertension
DrugMacitentan
Actelion
Phase 3
935
Prague
2020-06-30
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
996
Brno, Hradec Králové, Náchod, Olomouc, Ostrava, Prague, Zlín, Ústí nad Labem
2020-06-22
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511Alzheimer Disease
DrugDonanemab
Eli Lilly and Company
Phase 3
1,736
Hostivice, Kladno, Pilsen, Prague
2020-06-19
Rows per page Showing 1201–1300 of 1510
Previous 11 12 13 14 15 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Czech investigative site. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-czechia?page=13

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Czechia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,510 studies in total at the last sync on 26 Sep 2026, 19:45 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in Czechia?

786 of the 1,510 studies in this register are recruiting new participants as of the 26 Sep 2026, 19:45 UTC sync. A further 59 have not yet opened recruitment, 606 are active but closed to new participants, and 59 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Multiple Myeloma (30) Heart Failure (27) Obesity (27) Ulcerative Colitis (24) Crohn's Disease (23) Breast Cancer (17) Chronic Lymphocytic Leukemia (17) Atrial Fibrillation (16) Overweight (15) Atopic Dermatitis (14) Multiple Sclerosis (13) Small Lymphocytic Lymphoma (13) Ovarian Cancer (13) Carcinoma, Non-Small-Cell Lung (12) Myelodysplastic Syndromes (11)
→

Browse trials by site location

Prague (1080) Brno (606) Olomouc (325) Hradec Králové (320) Ostrava (279) Pilsen (113) Pardubice (91) České Budějovice (64) Zlín (46) Nový Jičín (45) Uherské Hradiště (39) Liberec (35) Ostrava - Poruba (33) Náchod (33) Ústí nad Labem (32)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.